Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab in FGFR2b-positive Advanced or Metastatic Gastric or GEJ Adenocarcinoma
NCT06680622Phase 2Active, not recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Mar 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bemarituzumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 cohorts), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective Response Rate up to 33 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
bemarituzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06680622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680622.